Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Biosimilars for Cancer Treatment : A Promising Approach
| Biosimilars for Cancer Treatment : A Promising Approach |
| Autore | Bhatt Shvetank |
| Edizione | [1st ed.] |
| Pubbl/distr/stampa | Singapore : , : Springer, , 2024 |
| Descrizione fisica | 1 online resource (316 pages) |
| Altri autori (Persone) |
DurejaHarish
Gunvantbhai PatelSamir Samir PatelArchita DuaKamal |
| ISBN | 981-9730-01-5 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910869176203321 |
Bhatt Shvetank
|
||
| Singapore : , : Springer, , 2024 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Immunotherapy Against Lung Cancer [[electronic resource] ] : Emerging Opportunities and Challenges / / edited by Shvetank Bhatt, Rajaraman Eri Eri, Bey-Hing Goh, Keshav Raj Paudel, Terezinha de Jesus Andreoli Pinto, Kamal Dua
| Immunotherapy Against Lung Cancer [[electronic resource] ] : Emerging Opportunities and Challenges / / edited by Shvetank Bhatt, Rajaraman Eri Eri, Bey-Hing Goh, Keshav Raj Paudel, Terezinha de Jesus Andreoli Pinto, Kamal Dua |
| Autore | Bhatt Shvetank |
| Edizione | [1st ed. 2023.] |
| Pubbl/distr/stampa | Singapore : , : Springer Nature Singapore : , : Imprint : Springer, , 2023 |
| Descrizione fisica | 1 online resource (393 pages) |
| Disciplina | 616.994 |
| Altri autori (Persone) |
EriRajaraman Eri
GohBey-Hing PaudelKeshav Raj Andreoli PintoTerezinha de Jesus DuaKamal |
| Soggetto topico |
Cancer - Treatment
Tumors - Immunological aspects Cancer Therapy Tumour Immunology |
| ISBN | 981-9971-41-1 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Chapter 1_An introduction to Lung cancer -- Chapter 2_Immunobiology of Lung cancer -- Chapter 3_Evolution of Lung cancer treatment from classical chemotherapy to advanced immunotherapy -- Chapter 4_Recent advances in the immunotherapy of Lung cancer -- Chapter 5_PD-1/PD-L1 inhibitors for the treatment of Lung cancer -- Chapter 6_CTLA-4 inhibitors for the treatment of Lung cancer -- Chapter 7_Adoptive T cell therapy for the treatment of Lung cancer -- Chapter 8_LAG-3 inhibitors for the treatment of Lung cancer -- Chapter 9_IDO and TGF-β inhibitors for the treatment of Lung cancer -- Chapter 10_OX40 and CD40 agonists for the treatment of Lung cancer -- Chapter 11_ICOS and GITR agonists for the treatment of Lung cancer -- Chapter 12_Vaccines and oncolytic virus for the treatment of Lung cancer.-Chapter 13_Targeting Toll-like receptors for the treatment of Lung cancer -- Chapter 14_Current and future perspectives of combining chemotherapy and stereotactic body radiation therapy with immunotherapy -- Chapter 15_Synergistic potential of PD-1/PD-L1 inhibitors and CTLA-4 inhibitors for the treatment of Lung cancer -- Chapter 16_Synergistic potential of antigen-specific vaccines and immunomodulatory agents for the treatment of Lung cancer -- Chapter 17_Important biomarkers for better evaluation of checkpoint inhibitors and another immunotherapy in Lung cancer -- Chapter 18_Insight on the clinical trials of immunotherapy for the treatment of Lung cancer -- Chapter 19_Future perspectives of the Cancer Immunotherapy for the treatment of Lung cancer. |
| Record Nr. | UNINA-9910845494503321 |
|
Bhatt Shvetank
|
||
| Singapore : , : Springer Nature Singapore : , : Imprint : Springer, , 2023 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Immunotherapy Against Lung Cancer [[electronic resource] ] : Emerging Opportunities and Challenges / / edited by Shvetank Bhatt, Rajaraman Eri Eri, Bey-Hing Goh, Keshav Raj Paudel, Terezinha de Jesus Andreoli Pinto, Kamal Dua
| Immunotherapy Against Lung Cancer [[electronic resource] ] : Emerging Opportunities and Challenges / / edited by Shvetank Bhatt, Rajaraman Eri Eri, Bey-Hing Goh, Keshav Raj Paudel, Terezinha de Jesus Andreoli Pinto, Kamal Dua |
| Autore | Bhatt Shvetank |
| Edizione | [1st ed. 2023.] |
| Pubbl/distr/stampa | Springer Nature Singapore, 2023 |
| Descrizione fisica | 1 online resource (393 pages) |
| Disciplina | 616.994 |
| Altri autori (Persone) |
EriRajaraman Eri
GohBey-Hing PaudelKeshav Raj Andreoli PintoTerezinha de Jesus DuaKamal |
| Soggetto topico |
Cancer - Treatment
Tumors - Immunological aspects Cancer Therapy Tumour Immunology |
| ISBN | 981-9971-41-1 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Chapter 1_An introduction to Lung cancer -- Chapter 2_Immunobiology of Lung cancer -- Chapter 3_Evolution of Lung cancer treatment from classical chemotherapy to advanced immunotherapy -- Chapter 4_Recent advances in the immunotherapy of Lung cancer -- Chapter 5_PD-1/PD-L1 inhibitors for the treatment of Lung cancer -- Chapter 6_CTLA-4 inhibitors for the treatment of Lung cancer -- Chapter 7_Adoptive T cell therapy for the treatment of Lung cancer -- Chapter 8_LAG-3 inhibitors for the treatment of Lung cancer -- Chapter 9_IDO and TGF-β inhibitors for the treatment of Lung cancer -- Chapter 10_OX40 and CD40 agonists for the treatment of Lung cancer -- Chapter 11_ICOS and GITR agonists for the treatment of Lung cancer -- Chapter 12_Vaccines and oncolytic virus for the treatment of Lung cancer.-Chapter 13_Targeting Toll-like receptors for the treatment of Lung cancer -- Chapter 14_Current and future perspectives of combining chemotherapy and stereotactic body radiation therapy with immunotherapy -- Chapter 15_Synergistic potential of PD-1/PD-L1 inhibitors and CTLA-4 inhibitors for the treatment of Lung cancer -- Chapter 16_Synergistic potential of antigen-specific vaccines and immunomodulatory agents for the treatment of Lung cancer -- Chapter 17_Important biomarkers for better evaluation of checkpoint inhibitors and another immunotherapy in Lung cancer -- Chapter 18_Insight on the clinical trials of immunotherapy for the treatment of Lung cancer -- Chapter 19_Future perspectives of the Cancer Immunotherapy for the treatment of Lung cancer. |
| Record Nr. | UNINA-9910853990503321 |
|
Bhatt Shvetank
|
||
| Springer Nature Singapore, 2023 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Medicinal plants for lung diseases : a pharmacological and immunological perspective / / Kamal Dua [and five others], editors
| Medicinal plants for lung diseases : a pharmacological and immunological perspective / / Kamal Dua [and five others], editors |
| Pubbl/distr/stampa | Singapore : , : Springer, , [2021] |
| Descrizione fisica | 1 online resource (625 pages) |
| Disciplina | 616.248 |
| Soggetto topico |
Emphysema, Pulmonary - Alternative treatment
Lungs - Diseases, Obstructive - Alternative treatmenT Malalties del pulmó Plantes medicinals Medicina alternativa Quimioteràpia |
| Soggetto genere / forma | Llibres electrònics |
| ISBN | 981-336-850-0 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910494558003321 |
| Singapore : , : Springer, , [2021] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Role of Oxidative Stress in Pathophysiology of Diseases / / edited by Pawan K. Maurya, Kamal Dua
| Role of Oxidative Stress in Pathophysiology of Diseases / / edited by Pawan K. Maurya, Kamal Dua |
| Edizione | [1st ed. 2020.] |
| Pubbl/distr/stampa | Singapore : , : Springer Singapore : , : Imprint : Springer, , 2020 |
| Descrizione fisica | 1 online resource (303 pages) |
| Disciplina | 616.39 |
| Soggetto topico |
Oxidative stress
Human physiology Cancer research Diabetes Neurosciences Nanotechnology Oxidative Stress Human Physiology Cancer Research Fisiologia patològica Estrès oxidatiu |
| Soggetto genere / forma | Llibres electrònics |
| ISBN | 981-15-1568-9 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Chapter 1. Oxidative stress and oral diseases -- Chapter 2. Role of Oxidative stress in Chronic Liver Diseases -- Chapter 3. In-vitro and In-vivo Antioxidant activity of nanoparticles -- Chapter 4. Oxidative stress in neurology and neurodegenerative processes -- Chapter 5. The role of oxidative stress in respiratory diseases -- Chapter 6. Role of Synbiotics in alleviating oxidative stress in colorectal cancer -- Chapter 7. Oxidative Stress and Immunological Complexities in Multi-Drug Resistant Tuberculosis -- Chapter 8. Infection-induced Oxidative Stress in Chronic Respiratory Diseases -- Chapter 9. Oxidative stress in neuropsychiatric and neurodegenerative diseases -- Chapter 10. Oxidative stress monitoring in in vitro and in vivo models -- Chapter 11. Effects of Yoga on Aging. |
| Record Nr. | UNINA-9910409682603321 |
| Singapore : , : Springer Singapore : , : Imprint : Springer, , 2020 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Targeting cellular signalling pathways in lung diseases / / Kamal Dua [and four others], editors
| Targeting cellular signalling pathways in lung diseases / / Kamal Dua [and four others], editors |
| Pubbl/distr/stampa | Gateway East, Singapore : , : Springer, , [2021] |
| Descrizione fisica | 1 online resource (921 pages) |
| Disciplina | 616.2407 |
| Soggetto topico | Lungs - Diseases - Molecular aspects |
| ISBN | 981-336-827-6 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Intro -- Preface -- Acknowledgment -- Contents -- About the Editors -- 1: Introduction to Lung Diseases -- 1.1 Chronic Obstructive Pulmonary Disorder (COPD) -- 1.1.1 Definition -- 1.1.2 Epidemiology -- 1.1.3 Causes -- 1.1.4 Symptoms (Fig. 1.2) -- 1.1.5 Pathophysiology -- 1.1.6 Treatment -- 1.2 Asthma -- 1.2.1 Definition -- 1.2.2 Epidemiology -- 1.2.3 Causes (Fig. 1.3) -- 1.2.4 Symptoms (Fig. 1.4) -- 1.2.5 Pathophysiology -- 1.2.6 Types of Asthma [40] -- 1.2.7 Treatment -- 1.3 Lung Cancer -- 1.3.1 Classification -- 1.3.2 Epidemiology -- 1.3.3 Etiology and Risk Factors [45] (Fig. 1.6) -- 1.3.4 Sign and Symptoms -- 1.3.5 Diagnosis -- 1.3.6 Staging of Lung Cancer -- 1.3.7 Treatment [54] -- 1.4 Acute Respiratory Tract Infections -- 1.4.1 Upper Respiratory Tract Infections -- 1.4.1.1 Acute Pharyngitis -- 1.4.1.2 Acute Sinusitis -- 1.4.1.3 Acute Viral Laryngitis -- 1.4.2 Lower Respiratory Tract Infection -- 1.4.2.1 Pneumonia -- 1.4.2.2 Influenza -- 1.5 Idiopathic Pulmonary Fibrosis (IPF) -- 1.5.1 Epidemiology -- 1.5.2 Causes -- 1.5.3 Pathophysiology -- 1.5.4 Symptoms -- 1.5.5 Diagnosis -- 1.5.6 Treatment -- References -- 2: Targeting Molecular and Cellular Mechanisms in Asthma -- 2.1 Introduction -- 2.1.1 Rationale to the Study -- 2.1.2 Asthma: A Global Health Burden -- 2.1.3 Asthma: GINA Definition -- 2.2 Traditional Understanding and Parallel Non-specific Therapy -- 2.2.1 Major Types of Asthma -- 2.2.2 Allergens Are Major Inducers for Atopic Asthma -- 2.2.3 Pathophysiology -- 2.2.4 Symptomatic Therapy -- 2.3 Current Understanding and Steps Towards Pathway-Specific Therapy(Fig. 2.1) -- 2.3.1 Cells Involved in Asthma Pathogenesis and Respective Targets -- 2.3.1.1 Airway Epithelium -- 2.3.1.2 Dendritic Cells -- Dendritic Cell Modulator as a Target -- 2.3.1.3 Lymphocytes -- 2.3.1.4 T Helper Type 2 (Th2) Cells -- Th2 Cytokines as Target.
2.3.1.5 B Lymphocytes and IgE -- 2.3.1.6 Mast Cells -- 2.3.2 Th2-High Eosinophilic Asthma Versus Th2-Low Neutrophilic Asthma -- 2.3.2.1 Eosinophilic Asthma/Th2-High Asthma -- 2.3.2.2 Neutrophilic Asthma -- 2.3.3 Asthma: A Complex Syndrome with Multiple Endotypes -- 2.4 Nitro-Oxidative Stress in Asthma Pathogenesis -- 2.4.1 Oxidative Stress -- 2.4.2 Mitochondrial Dysfunction in Asthma -- 2.4.3 Nitric Oxide (NO) -- 2.5 Airway Remodelling in Asthma: The Knowledge that Will Shape the Future Treatment -- 2.6 Non-pharmacological Intervention for Asthma: Bronchial Thermoplasty -- 2.7 Tailoring the Patient Needs Via `Personalised Approach´ in Asthma -- 2.8 Conclusions and Future Perspectives -- References -- 3: Various Cellular and Molecular Axis Involved in the Pathogenesis of Asthma -- 3.1 Introduction -- 3.2 Epidemiology and Risk Factors -- 3.3 Granulocytes: As Predictors of Asthma -- 3.3.1 Basophils and Allergic Inflammation -- 3.3.1.1 Stimuli for Basophil Activation -- 3.3.1.2 Inflammatory Mediators of Basophils -- 3.3.1.3 Basophil Adhesion Molecules -- 3.3.2 Neutrophil Granule Contents -- 3.3.2.1 Mechanisms in Neutrophil Activation -- 3.3.2.2 Neutrophil in Airway Inflammation and its Signal Transduction Pathways -- 3.3.2.3 Neutrophil Apoptosis: The Resolution of Inflammation -- 3.3.3 Eosinophilic Asthma -- 3.3.3.1 Eosinophil-Derived Cytokines and Associated Bronchial Hyperresponsiveness -- 3.4 Fibroblasts and Myofibroblasts -- 3.4.1 Extracellular Matrix Production in the Airways -- 3.4.2 Fibroblast to Myofibroblast Transition -- 3.5 Pathological Signaling Pathways Involved in the Activation of Lung-Resident Macrophages and Dendritic Cells (DCs) -- 3.5.1 Macrophage Activation Pathways -- 3.5.1.1 IL-4/IL-13 Signaling Pathway -- 3.5.1.2 TNF-α Signaling Pathway -- 3.5.1.3 TGF-β Signaling Pathway -- 3.5.2 Reactive Oxygen and Nitrogen Species. 3.5.3 Antigen Presentation by Dendritic Cells and their Role in the Pathology of Asthma -- 3.6 Bronchial Epithelial Cells -- 3.6.1 Mechanisms of Endothelial Cell Activation -- 3.6.1.1 Cytokine Activation -- 3.6.1.2 Role of Epithelial Cells in Type 2-Driven and Non-type 2 Allergic Asthma -- 3.7 Airway Epithelial and Smooth Muscle Cells -- 3.7.1 Physiological Barrier -- 3.7.2 Airway Epithelial Cell-Derived Mediators -- 3.7.2.1 Nitric Oxide (NO) -- 3.7.2.2 Endothelin -- 3.7.2.3 Arachidonic Acid Metabolites -- 3.7.2.4 Inflammatory Cytokines -- 3.7.2.5 Cell Adhesion Molecules -- 3.7.2.6 Platelet-Activating Factor (PAF) -- 3.7.2.7 Tachykinin -- 3.7.2.8 Histamine -- 3.7.2.9 Adenosine -- 3.8 Role of Innate Immunity in Asthma -- 3.8.1 CD4+ and CD8+ T Cells in Asthma -- 3.8.2 Cellular Receptors of Innate Immunity in Asthma -- 3.8.3 Innate-like T Cells and Asthma -- 3.9 Conclusion -- References -- 4: Targeting Molecular and Cellular Mechanisms in Steroid-Resistant Asthma -- 4.1 Introduction -- 4.2 Inducers of Steroid Resistance in Asthma -- 4.3 Shedding Light on the Cellular Mechanisms Underlying the Glucocorticoid Receptor Signalling Pathway-Mediated Steroid Resis... -- 4.3.1 Neutrophils -- 4.3.2 Factors Inducing Airway Neutrophilia -- 4.3.3 Eosinophils -- 4.3.4 Group 2 Innate Lymphoid Cells (ILC-2) -- 4.3.5 T Helper Type 9 Cells (Th9 Cells) -- 4.3.6 CD8+ T Cells -- 4.4 Possible Molecular Mechanisms behind Steroid-Resistant (SR) Asthma (Fig. 4.1) -- 4.4.1 Bioavailability of Glucocorticoid Receptor (GR) and the Underlying Molecular Mechanism -- 4.4.2 IL-17A High and IFN-γ High Phenotypes -- 4.4.3 PI3K/HDAC Signalling Pathway -- 4.4.4 p38 MAPK -- 4.4.5 NLPR3 Inflammasome -- 4.4.6 Lack of Autophagy -- 4.4.7 Other Key Mechanisms -- 4.5 Tailoring Steroid-Refractory Asthma: The Possible Diagnosis and Therapeutics -- 4.5.1 Immunosuppressive Drugs. 4.5.2 Biologic Therapies -- 4.5.3 Highly Potent Glucocorticoids -- 4.5.4 Vitamin D -- 4.5.5 Sulforaphane -- 4.6 Conclusions and Future Outlook -- References -- 5: Targeting Molecular and Cellular Mechanisms in Chronic Obstructive Pulmonary Disease -- 5.1 Introduction -- 5.2 Pathophysiology of COPD -- 5.2.1 Inflammatory Mediators and Cells -- 5.2.1.1 Neutrophils (NPHs) -- 5.2.1.2 Macrophages (MPs) -- 5.2.1.3 T-Lymphocyte -- Eosinophils (Eos) -- 5.2.1.4 Dendritic Cells (DCs) -- 5.2.1.5 Epithelial Cells (EP) -- 5.2.2 Protease and Antiprotease Imbalance -- 5.2.3 Oxidative Stress (OS) -- 5.3 Mediators Involved in COPD -- 5.3.1 Lipid Mediators -- 5.3.1.1 Prostaglandin -- 5.3.1.2 Thromboxane -- 5.3.1.3 Leukotrienes (LT) -- 5.3.1.4 Platelet-Activating Factor (PAF) -- 5.3.2 Peptide Mediators -- 5.3.2.1 Endothelins (ET) -- 5.3.2.2 Bradykinin (BK) -- 5.3.2.3 Tachykinins (TK) -- 5.3.2.4 Chemokines -- 5.3.2.5 Interleukin-8 (IL-8) -- 5.4 Potential Targets and Therapies for COPD -- 5.4.1 PDE (Phosphodiesterase) Inhibitors -- 5.4.2 Hypersecretion of Mucus -- 5.4.3 Bronchodilators -- 5.4.4 Glucocorticoids (Inhaled Corticosteroids) -- 5.4.5 Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) -- 5.4.5.1 CXCR2 Inhibitors -- 5.4.6 Phosphoinositide-3 Kinase Delta (PI3K) Inhibitor -- 5.4.7 Targeting Inflammatory Markers -- 5.4.8 Other COPD Treatments -- 5.5 Conclusion -- References -- 6: Probing the Cellular and Molecular Mechanisms Underlying in the Pathogenesis of Chronic Obstructive Pulmonary Disease -- 6.1 Introduction -- 6.2 Subtypes of COPD -- 6.2.1 Chronic Bronchitis -- 6.2.2 Emphysema -- 6.2.3 Small Airway Disease -- 6.3 Inflammatory Cells Involved in COPD -- 6.3.1 Epithelial Cells -- 6.3.2 Macrophages -- 6.3.3 Neutrophils -- 6.3.4 Eosinophil -- 6.3.5 Dendritic Cells -- 6.3.6 T-Lymphocytes -- 6.4 Inflammatory Mediators Involved in COPD. 6.4.1 Lipid Mediators -- 6.4.2 Pro-inflammatory Cytokines -- 6.4.3 Inflammasomes -- 6.4.4 Role of Reactive Oxygen Species (ROS) and Oxidative Stress in COPD -- 6.5 Conclusion -- References -- 7: Chronic Obstructive Pulmonary Disease: Molecular Basis of Pathogenesis and Targeted Therapeutic Approaches -- 7.1 Introduction -- 7.2 Epidemiology -- 7.3 Aetiology of Disease Progression -- 7.3.1 Inflammation -- 7.3.1.1 Neutrophils -- 7.3.1.2 Macrophages -- 7.3.1.3 T Lymphocytes -- 7.3.1.4 Eosinophils -- 7.3.1.5 Dendritic Cells -- 7.3.1.6 Epithelial Cells -- 7.3.2 Oxidative Stress -- 7.3.3 Genetic Predisposition -- 7.3.4 Epigenetics -- 7.3.5 Activity of Proteases -- 7.3.5.1 Neutrophil Wlastase -- 7.3.5.2 Cysteine Proteases -- 7.3.5.3 Matrix Metalloproteinases -- 7.4 Current Treatments and Their Drawbacks -- 7.4.1 Quit Smoking -- 7.4.2 Vaccination -- 7.4.3 Physical Activity -- 7.4.4 Pharmacological Treatment -- 7.4.5 Emerging Antioxidants for an Alternative Therapeutic Approach -- 7.4.6 Interventional Treatments -- 7.4.7 Oxygen and Ventilator Support -- 7.4.8 Comorbidity Treatment -- 7.5 Conclusion -- References -- 8: Exploring the `Dormancy Activation Switch´ in the Tumour Microenvironment for Metastatic Lung Cancer: The Possible Role of ... -- 8.1 Lung Cancer -- 8.2 Metastatic Niche in Different Sites -- 8.3 Lymph Node Metastasis -- 8.3.1 MAPK Signalling in Lymph Node Metastasis of Lung Cancer -- 8.4 Pleura Metastasis -- 8.4.1 CXCR4/CXCL12 Signalling and Pleura Metastasis in Lung Cancer -- 8.5 Liver Metastasis -- 8.5.1 ALK and Liver Metastasis in Lung Cancer -- 8.6 Brain Metastasis -- 8.6.1 Rho/ROCK Signalling and Brain Metastasis in Lung Cancer -- 8.6.2 PI3K/AKT Signalling and Brain Metastasis in Lung Cancer -- 8.7 Bone Metastasis -- 8.7.1 RANK/RANKL Signalling and Bone Metastasis in Lung Cancer -- 8.8 Controversial Role miRNA in Lung Cancer Metastasis. 8.9 Concluding Remarks. |
| Record Nr. | UNINA-9910488713203321 |
| Gateway East, Singapore : , : Springer, , [2021] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Understanding Allergic Airway Diseases : Contemporary Treatment Paradigm / / edited by Parteek Prasher, Mousmee Sharma, Sachin Kumar Singh, Ronan MacLoughlin, Kavita Pabreja, Kamal Dua
| Understanding Allergic Airway Diseases : Contemporary Treatment Paradigm / / edited by Parteek Prasher, Mousmee Sharma, Sachin Kumar Singh, Ronan MacLoughlin, Kavita Pabreja, Kamal Dua |
| Autore | Prasher Parteek |
| Edizione | [1st ed. 2024.] |
| Pubbl/distr/stampa | Singapore : , : Springer Nature Singapore : , : Imprint : Springer, , 2024 |
| Descrizione fisica | 1 online resource (271 pages) |
| Disciplina | 616.202 |
| Altri autori (Persone) |
SharmaMousmee
SinghSachin Kumar MacLoughlinRonan PabrejaKavita DuaKamal |
| Soggetto topico |
Pharmacology
Pharmaceutical chemistry Pharmacovigilance Immunology Nanotechnology Quantum dots Pharmaceutics Drug Safety and Pharmacovigilance Quantum Dots |
| ISBN |
9789819719532
9789819719525 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Chapter 1. Introduction to Allergic Airway Diseases -- Chapter 2. Pathophysiology of Allergic airway diseases -- Chapter 3. Immunology of Allergic Airway Diseases -- Chapter 4. Epidemiology of Allergic Airway Diseases -- Chapter 5. Nanotechnology in the Diagnosis of Allergic Airway Diseases -- Chapter 6. Metal and metal oxide Nanoparticles for the Management of Allergic Airway Diseases -- Chapter 7.-Nanomicelles for the Management of Allergic Airway Diseases -- Chapter 8 -- Carbon nanotubes (CNTs): A novle therapeutic approach in the management of allergic airway disease -- Chapter 9. Liposomes for the Management of Allergic Airway Diseases -- Chapter 10. Nanoparticles Solutions for Allergic Airway Disorders: Current Trends and Future Prospects -- Chapter 11. Solid lipid nanoparticles for the Management of Allergic Airway Diseases -- Chapter 12. Role of Dendrimers in Management of Allergic Airway Diseases -- Chapter 13. Nanofibers for the Management of Allergic Airway Diseases -- Chapter 14. Quantum dots for the Management of Allergic Airway Diseases -- Chapter 15. Future Directions in Allergic Airway Diseases. |
| Record Nr. | UNINA-9910869168903321 |
|
Prasher Parteek
|
||
| Singapore : , : Springer Nature Singapore : , : Imprint : Springer, , 2024 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||